Dr. Ronald Tutrone has authored numerous articles in the urology literature. He has been principal investigator in more than 200 clinical research trials, including a recent trial involving the ExoDx Prostate (EPI) test published in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of the exosome based ExoDx™ Prostate (IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10ng/mL.
The study demonstrated that EPI delivered improved patient outcomes over standard of care in a real-world clinical setting that included 72 urologists, 24 sites and more than 1000 patients. The study is the first ever prospective, multi-center, randomized prostate biomarker trial with a blinded control arm conducted in a clinical utility setting. The study was a collaboration between the largest urology practice in Maryland, Chesapeake Urology, and CareFirst Blue Cross Blue Shield.